The GLP-1 peptide will be marketed in the UK under the brand names Liraglutide Biocon for diabetes and Biolide for chronic weight management. The launch follows the approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), UK, earlier this year. Shares of Biocon were trading 3.17 per cent down at Rs 302.15 apiece on BSE on Friday. The company will continue to focus its efforts towards expanding the reach of gLiragLutide into other European markets, the US and select geographies, it added. The drug is administered as a once-daily injection. It helps lower blood sugar levels and promote weight loss, the company said. The product is available in the US, Europe, Australia, New Zealand, Canada, Australia and New Zealand and is expected to be launched in India in the next few months, Biocon said. It is the first generics drug to be approved in a major regulated market in the U.S.
